
Episode 742: John Feneck on Silver, Gold, and Under-the-Radar Mining Opportunities
19.12.2025 | 21 min.
Gold and silver are reaching new highs in 2025, but several opportunities may still be under the radar.tFeneck Consulting Group CEO John Feneck discusses how he’s navigating today’s precious metals cycle, global banks’ 2026 forecasts, the growing importance of critical minerals amid shifting economic and geopolitical conditions, and select development and exploration prospects.To learn more about John Feneck’s track record, visit the Feneck Consulting performance page: https://www.feneckconsulting.com/performanceWatch the full YouTube interview here: https://youtu.be/EVst6ATfZAMAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Episode 741: Rua Gold ($RUA) CEO Discusses Project Portfolio and 2026 Catalysts
19.12.2025 | 13 min.
Rua Gold (TSXV: RUA | OTC: NZAUF | WKN: A40QYC) is unlocking some of the most prospective gold in New Zealand, with two flagship assets: the Reefton and Glamorgan Projects.In this interview, CEO & Director Robert Eckford discusses the company’s investment highlights, projects, 2026 catalysts, and more.Learn more: https://ruagold.com/Watch the full YouTube interview here: https://youtu.be/UlKIzrkwSDoAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Episode 740: GT Biopharma ($GTBP) CEO on Expanding Into Solid Tumors and Key 2026 Catalysts
18.12.2025 | 17 min.
Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body’s natural immune response.Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company’s next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Episode 739: Copper Fox Metals ($CUU) on Key Milestones and What’s Ahead for 2026
17.12.2025 | 14 min.
Two big projects, rising metal prices, and a possible re-rate on the horizon. Is Copper Fox Metals (TSXV: CUU | OTCQX: CPFXF | FSE: HPU) on the verge of a major step up in 2026?In this interview, Copper Fox Metals CEO Elmer B. Stewart breaks down their progress at Van Dyke and Schaft Creek. He also explains why 2025 was a turning point, what to expect in 2026, and why the company believes it is still undervalued.Stay tuned to find out what this means for investors and why the company sees room for a strong re-rating ahead.Learn more about Copper Fox Metals: https://copperfoxmetals.comWatch the full YouTube interview here: https://youtu.be/-smfMC9EaZQAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Episode 739: Copper Fox Metals ($CUU) on Key Milestones and What’s Ahead for 2026
17.12.2025 | 14 min.
Two big projects, rising metal prices, and a possible re-rate on the horizon. Is Copper Fox Metals (TSXV: CUU | OTCQX: CPFXF | FSE: HPU) on the verge of a major step up in 2026?In this interview, Copper Fox Metals CEO Elmer B. Stewart breaks down their progress at Van Dyke and Schaft Creek. He also explains why 2025 was a turning point, what to expect in 2026, and why the company believes it is still undervalued.Stay tuned to find out what this means for investors and why the company sees room for a strong re-rating ahead.Learn more about Copper Fox Metals: https://copperfoxmetals.comWatch the full YouTube interview here: https://youtu.be/-smfMC9EaZQAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia



Stocks To Watch